prikaz prve stranice dokumenta Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom
  Download
PDF 857.9 KB
master's thesis
Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom
Zagreb: University of Zagreb, School of Medicine, 2022. urn:nbn:hr:105:314397
Matošević, Matija
University of Zagreb
School of Medicine
Department of Internal Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Matošević, M. (2022). Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:314397

Matošević, Matija. "Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom." Master's thesis, University of Zagreb, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:105:314397

Matošević, Matija. "Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom." Master's thesis, University of Zagreb, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:105:314397

Matošević, M. (2022). 'Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom', Master's thesis, University of Zagreb, School of Medicine, accessed 27 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:314397

Matošević M. Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2022 [cited 2024 December 27] Available at: https://urn.nsk.hr/urn:nbn:hr:105:314397

M. Matošević, "Liječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:105:314397

Metadata
TitleLiječenje hemolitičko uremijskog sindroma ekulizumabom ili ravulizumabom
Title (english)Treatment of hemolytic-uremic syndrome with eculizumab or ravulizumab
AuthorMatija Matošević
MentorIvana Vuković Brinar (mentor)
Committee memberAna Boban (predsjednik povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
Committee memberIvana Vuković Brinar (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Zagreb
Defense date and country2022-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Hemolitičko-uremijski sindrom predstavlja tešku i rijetku skupinu bolesti čije je zajedničko, osnovno patološko obilježje pojava trombotičke mikroangiopatije. Hemolitičko-uremijski sindrom karakterizira trijas koji uključuje perifernu trombocitopeniju, mehaničku hemolitičku anemiju i ozljedu organa, prvenstveno bubrega i mozga. Postoje brojne klasifikacije, ali danas je najčešća klasifikacija Međunarodnog društva za hemolitičko-uremijski sindrom iz 2016. godine.. Posebno treba istaknuti atipični hemolitičko-uremijski sindrom, zbog njegove opširne genetske podloge i etiologije vezane uz sustav komplementa. Klinička slika ovisi o uzroku same bolesti, kao i pristup dijagnostici i liječenju. Ekulizumab i ravulizumab monoklonska su protutijela koja blokiraju C5 komponentu komplementa te se koriste u liječenju atipičnog hemolitičko uremijskog sindroma. Svrha ovog rada je napraviti pregled hemolitičko-uremijskog sindroma, s posebnim naglaskom na atipični hemolitičko-uremijski sindrom i njegovo liječenje monoklonskim protutijelima ekulizumabom i ravulizumabom uz usporedbu ove dvije terapije.
Abstract (english)
Hemolytic-uremic syndrome is a severe and rare group of diseases whose common, basic pathological feature is the occurrence of thrombotic microangiopathy. Hemolytic-uremic syndrome is characterized by a triad that includes peripheral thrombocytopenia, mechanical hemolytic anemia, and injury to organs, primarily kidney and brain. There are numerous classifications, but today the most common classification is the International Society for Hemolytic-Uremic Syndrome from 2016. Special emphasis should be put on atypical hemolytic-uremic syndrome, due to its extensive etiological and genetic background related to the complement system. The clinical presentation as well as the approach to diagnosis and treatment depends on the cause of the disease itself. Eculizumab and ravulizumab are monoclonal antibodies that block the C5 component of complement and are used to treat atypical hemolytic-uremic syndrome. The purpose of this paper is to review hemolytic-uremic syndrome, with special emphasis on atypical hemolytic-uremic syndrome and its treatment with monoclonal antibodies eculizumab and ravulizumab, with special emphasis on the comparison of two drugs.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:314397
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-01-19 09:36:05